Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pharmacology and Therapeutics

Angiotensin II Type 1 Receptor Blockade Improves β-Cell Function and Glucose Tolerance in a Mouse Model of Type 2 Diabetes

  1. Kwan Yi Chu1,
  2. Tung Lau1,
  3. Per-Ola Carlsson2 and
  4. Po Sing Leung1
  1. 1Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China
  2. 2Departments of Medical Cell Biology and Medical Sciences, Uppsala University, Uppsala, Sweden
  1. Address correspondence and reprint requests to Professor P. S. Leung, PhD, Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. E-mail: psleung{at}cuhk.edu.hk
Diabetes 2006 Feb; 55(2): 367-374. https://doi.org/10.2337/diabetes.55.02.06.db05-1022
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Immunohistochemical localization of AT1R and insulin in mouse pancreatic islets. A: AT1R immunoreactivity (red). B: Insulin immunoreactivity (blue). Insert: a merge image of AT1R and insulin in control islets. C: AT1R (red) in db/db islets. D: Insulin (blue) in db/db islets. Negative control for AT1R (E) and insulin (F) antibody. Magnification: Bar = 40 μm.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Real-time RT-PCR analysis of AT1R mRNA expression in control and db/db islets. The relative expression was normalized as percentage of 18S rRNA calculated using the comparative threshold cycle method of 2−ΔΔCT. All data are expressed as means ± SE; n = 7 in each group. *P < 0.001 vs. control.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Insulin release from isolated islets of control (ctl) and db/db mice. Effects of losartan (Los) and angiotensin II (AngII) on insulin release in 1.7 mmol/l (L) or 16.7 mmol/l (H) glucose from isolated islets of control mice (A) and db/db mice (B). C: Comparison of insulin release in control and diabetic mice. All values are given as means ± SE; n = 6–8 per group. *P < 0.05 vs. islets exposed to 1.7 mmol/l glucose only; †P < 0.05 vs. islets exposed to 16.7 mmol/l glucose only.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    (Pro)insulin biosynthesis from isolated islets of control (ctl) and diabetic mice. Effects of losartan (Los) and angiotensin II (AngII) on (pro)insulin biosynthesis in 1.7 mmol/l (L) or 16.7 mmol/l (H) glucose from isolated islets of control mice (A) and db/db mice (B). C: Comparison of (pro)insulin biosynthesis in control and db/db mice. All values are given as means ± SE; n = 5–8 each group. *P < 0.001 vs. islets exposed to 1.7 mmol/l glucose only; †P < 0.05 vs. islets exposed to 16.7 mmol/l glucose only.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Effect of losartan on plasma glucose levels. A: 4-week-old db/db mice were treated with losartan (0, 1, 5, 10, or 20 mg · kg−1 · day−1 for 8 weeks, n = 6–10). B: Plasma glucose levels of control and db/db mice treated with 10 mg · kg−1 · day−1 losartan or water only were measured twice a week for 8 weeks from the age of 4 weeks. All values are given as means ± SE; n = 10–11 per group. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the corresponding animals treated with water only.

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Effect of daily losartan treatment (10 mg/kg) on OGTT in control and db/db mice. A: Plasma glucose concentrations in mice undergoing an OGTT (1 g/kg) after treatment with losartan or water only for 8 weeks. B: The areas under the curves (AUC) were expressed and compared. All values are given as means ± SE; n = 10–11 per group. *P < 0.001 vs. the corresponding animals treated with water only.

  • FIG. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Effect of daily losartan treatment (10 mg/kg) on insulin tolerance in db/db mice. Glucose concentrations in mice undergoing insulin tolerance test (intraperitoneal insulin injection 2 units/kg) after treatment with losartan or water only for 8 weeks did not differ significantly; n = 6 per group.

Tables

  • Figures
  • TABLE 1

    AT1R expression in control and db/db islets using the comparative threshold cycle method

    GeneCT*ΔCT†ΔΔCT‡Expression relative to control§
    Control
        AT1R26.52 ± 0.626.62 ± 0.48
        18S19.79 ± 0.53
    Diabetes
        AT1R24.54 ± 1.646.15 ± 0.76−0.47 ± 0.773.06
        18S18.35 ± 0.95
    • Data are means ± SE.

    • *

      * Sample average of threshold cycle (CT) data.

    • †

      † The ΔCT value was calculated by the subtraction of the 18S rRNA CT from each sample CT.

    • ‡

      ‡ The ΔΔCT value was calculated by subtraction of the control ΔCT from each transplanted sample ΔCT.

    • §

      § Calculated using the equation 2−ΔΔCT.

PreviousNext
Back to top

In this Issue

February 2006, 55(2)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Angiotensin II Type 1 Receptor Blockade Improves β-Cell Function and Glucose Tolerance in a Mouse Model of Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Angiotensin II Type 1 Receptor Blockade Improves β-Cell Function and Glucose Tolerance in a Mouse Model of Type 2 Diabetes
Kwan Yi Chu, Tung Lau, Per-Ola Carlsson, Po Sing Leung
Diabetes Feb 2006, 55 (2) 367-374; DOI: 10.2337/diabetes.55.02.06.db05-1022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Angiotensin II Type 1 Receptor Blockade Improves β-Cell Function and Glucose Tolerance in a Mouse Model of Type 2 Diabetes
Kwan Yi Chu, Tung Lau, Per-Ola Carlsson, Po Sing Leung
Diabetes Feb 2006, 55 (2) 367-374; DOI: 10.2337/diabetes.55.02.06.db05-1022
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
  • Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench
  • Anti-Insulin Receptor Antibodies Improve Hyperglycemia in a Mouse Model of Human Insulin Receptoropathy
Show more Pharmacology and Therapeutics

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.